The article focuses on the factors that hinders the gene therapy for recessive dysthropic epidermolysis bullosa (RBED). It states that RBED is a disease that threatens the quality of life and is related with increased mortality. Furthermore, it notes that the other option to retroviral gene therapy is trans-splicing.